Document is current
Any future updates will be listed below
-
Authors
Anisimov, Andrey https://orcid.org/0000-0003-0259-1273
Fang, Shentong https://orcid.org/0000-0002-3520-7007
Hemanthakumar, Karthik Amudhala https://orcid.org/0000-0001-6151-1005
Örd, Tiit
van Avondt, Kristof
Chevre, Raphael
Toropainen, Anu https://orcid.org/0000-0001-9292-5147
Singha, Prosanta
Gilani, Huda
Nguyen, Su D.
Karaman, Sinem https://orcid.org/0000-0002-0719-1773
Korhonen, Emilia A.
Adams, Ralf H. https://orcid.org/0000-0003-3031-7677
Augustin, Hellmut G. https://orcid.org/0000-0002-7173-4242
Öörni, Katariina https://orcid.org/0000-0002-9525-0250
Soehnlein, Oliver https://orcid.org/0000-0002-7854-0694
Kaikkonen, Minna U. https://orcid.org/0000-0001-6294-0979
Alitalo, Kari https://orcid.org/0000-0002-7331-0902
- License Information
-
More Information
Article History
Received: 14 February 2022
Accepted: 26 January 2023
First Online: 13 March 2023
Competing interests
: O.S. is named as a co-inventor on a patent on peptides disrupting chemokine heteromers (WO2017/077062A1) and two patents on peptides neutralizing extracellular histones (WO2019/122127 A1 and WO2021209465A1). These patents are outside the scope of the current manuscript. O.S. is a scientfic advisor to Novo Nordisk and ResoTher Pharma. The other authors declare no competing interests.
